• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Defining Standard of Care

Opinion
Video

Overview of Markov model, a tool used for calculating potential clinical outcomes and the associated costs, and its use in the REBYOTA study. The standard of care used in the study is also defined.

Dr. Paul Feuerstadt: What’s important to understand with RBL [live JSLM; Rebyota] and any study that considers a live biotherapeutic product is that it’s an add on therapy. So when we talk about the comparator group, the so-called standard of care, that’s a standard antimicrobial course — what the patient would have received previously without the add on therapy. … [The] control group is the standard of care for the antimicrobial and then the comparator group, the study group, is the group that has that antimicrobial plus a treatment like RBL. Within the pivotal phase 3 trial considering RBL, patients with one or more recurrences of C. diff all receive standard of care, had a washout period and then either received the placebo or RBL. Through a Bayesian analysis, the overall efficacy for RBL at eight weeks was 70.6% versus 57.5% in the placebo arm, achieving a statistically significant difference between the two which is why it was granted FDA approval. So with that foundational knowledge in mind, can you explain to us a little bit about what a Markov model is and how it applies to this study?

Dr. Michael Kobernick: [Yes,] Markov model is … a really complex statistical model that has been developed over the years … to apply statistics to clinical science and clinical evaluation. What it does is it takes potential clinical outcomes and it creates groups of them and then it creates a likelihood that one or the other will occur and the cost associated with that. … [In] C. diff, it really talks about the likelihood in cost of developing complications in groups that have, as you mentioned, the standard-of-care antibiotics in groups that have RBL as the add-on therapy. It generates cost associated with them that can then be interpreted to … [mean] we know this treatment is clinically effective but how much does it cost? Does it cost way too much to get a desired result? … There’s a lot to argue back and forth about the desired result and the cost or does it cost an appropriate amount? I think that’s the essence of the Markov model. It’s statistically valid. It’s an acceptable way, a very acceptable way to compare costs between treatment groups and it’s a very good adjunct, the clinical trial that you mentioned.

Transcript is AI-generated and edited for clarity and readability.

Related Videos
Video 8 - "Demographic Differences That Impact Care"
Video 7 - "Gaps in Diabetes Education and Self Efficacy"
Video 6 - "Developing Reimbursement Models for Digital Therapeutics"
Video 5 - "Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics"
Video 2 - "Bridging Care Gaps with Prescription Digital Therapeutics"
Video 1 - "Overview of Prescription Digital Therapeutics and Impact on Clinical Practice"
Video 4 - "Payer Challenges in Evaluating Digital Therapeutics"
Video 3 - "Industry Collaboration in Shaping Digital Therapeutics Standards"
Video 6 - "Key Takeaways and Unmet Needs in Diabetes Treatment"
Video 5 - "Allocation of Investment and Value-Based Arrangements in Diabetes Care "
© 2024 MJH Life Sciences

All rights reserved.